Verrica Pharmaceuticals Inc. - Common Stock, $0.0001 par value (VRCA)
CUSIP: 92511W207
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock, $0.0001 par value
- Shares outstanding
- 8,810,762
- Total 13F shares
- 194,004
- Share change
- +194,004
- Total reported value
- $102,830
- Price per share
- $0.53
- Number of holders
- 4
- Value change
- +$102,830
- Number of buys
- 4
Quarterly Holders Quick Answers
What is CUSIP 92511W207?
CUSIP 92511W207 identifies VRCA - Verrica Pharmaceuticals Inc. - Common Stock, $0.0001 par value in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
- Newer quarter: Q3 2025
Recent filing periods for CUSIP 92511W207:
Top shareholders of VRCA - Verrica Pharmaceuticals Inc. - Common Stock, $0.0001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC |
3/4/5
13D/G
|
10%+ Owner |
1.6%
from 13D/G
|
7,099,182
|
$51,398,078 | — | 27 Dec 2023 | |
| Caligan Partners LP |
13D/G
13F
|
Company |
10%
|
15,856,653
|
$7,769,760 | $0 | 31 Dec 2024 | |
| ARMISTICE CAPITAL, LLC |
13D/G
13F
|
Company |
10%
|
9,235,571
|
$7,480,813 | +$81,611 | 31 Mar 2025 | |
| John A. Stalfort III |
3/4/5
|
Director |
—
mixed-class rows
|
2,997,394
mixed-class rows
|
$4,609,548 | — | 22 Nov 2024 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
3%
|
2,807,346
|
$1,241,408 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
2.6%
|
2,361,321
|
$1,043,704 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
1.3%
|
1,227,554
|
$542,824 | — | 31 Mar 2025 | |
| Ted White |
3/4/5
|
PRESIDENT AND CEO, Director |
—
mixed-class rows
|
440,967
mixed-class rows
|
$531,279 | — | 26 Aug 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.1%
|
1,018,486
|
$450,402 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0.85%
|
790,163
|
$349,253 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.61%
|
567,048
|
$250,749 | — | 31 Mar 2025 | |
| Gary Goldenberg |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
174,261
mixed-class rows
|
$231,882 | — | 26 Aug 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.47%
|
434,748
|
$192,246 | — | 31 Mar 2025 | |
| Sovran Advisors, LLC |
13F
|
Company |
0.42%
|
392,163
|
$192,160 | — | 31 Mar 2025 | |
| Joe Bonaccorso |
3/4/5
|
CHIEF COMMERCIAL OFFICER |
—
mixed-class rows
|
153,114
mixed-class rows
|
$179,860 | — | 26 Aug 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.43%
|
395,651
|
$174,957 | — | 31 Mar 2025 | |
| Christopher G. Hayes |
3/4/5
|
CHIEF LEGAL OFFICER |
—
mixed-class rows
|
506,458
mixed-class rows
|
$114,698 | — | 14 Mar 2025 | |
| Terry Kohler |
3/4/5
|
CHIEF FINANCIAL OFFICER |
—
mixed-class rows
|
124,697
mixed-class rows
|
$109,955 | — | 26 Aug 2024 | |
| A. Brian Davis |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
12,900
|
$83,721 | — | 04 Jun 2021 | |
| BML Capital Management, LLC |
13F
|
Company |
0.19%
|
174,651
|
$77,231 | — | 31 Mar 2025 | |
| Mariner, LLC |
13F
|
Company |
0.18%
|
165,188
|
$73,046 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.15%
|
139,055
|
$61,490 | — | 31 Mar 2025 | |
| Kovitz Investment Group Partners, LLC |
13F
|
Company |
0.11%
|
101,125
|
$44,717 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.11%
|
99,505
|
$44,001 | — | 31 Mar 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.1%
|
88,674
|
$39,212 | — | 31 Mar 2025 | |
| Composition Wealth, LLC |
13F
|
Company |
0.09%
|
84,000
|
$37,145 | — | 31 Mar 2025 | |
| SteelPeak Wealth, LLC |
13F
|
Company |
0.08%
|
76,000
|
$33,608 | — | 31 Mar 2025 | |
| Invesco Ltd. |
13F
|
Company |
0.08%
|
74,388
|
$32,895 | — | 31 Mar 2025 | |
| BECK MACK & OLIVER LLC |
13F
|
Company |
0.08%
|
70,000
|
$30,954 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.08%
|
69,423
|
$30,699 | — | 31 Mar 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.06%
|
58,711
|
$25,962 | — | 31 Mar 2025 | |
| XTX Topco Ltd |
13F
|
Company |
0.06%
|
57,100
|
$25,250 | — | 31 Mar 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.06%
|
54,122
|
$23,933 | — | 31 Mar 2025 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.05%
|
50,000
|
$22,110 | — | 31 Mar 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.05%
|
44,383
|
$19,626 | — | 31 Mar 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.05%
|
43,613
|
$19,285 | — | 31 Mar 2025 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.04%
|
41,482
|
$18,000 | — | 31 Mar 2025 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.04%
|
34,941
|
$15,436 | — | 31 Mar 2025 | |
| SPC Financial, Inc. |
13F
|
Company |
0.03%
|
30,000
|
$13,266 | — | 31 Mar 2025 | |
| SG Americas Securities, LLC |
13F
|
Company |
0.03%
|
28,730
|
$13,000 | — | 31 Mar 2025 | |
| CITIGROUP INC |
13F
|
Company |
0.03%
|
29,110
|
$12,873 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.03%
|
25,351
|
$11,205 | — | 31 Mar 2025 | |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. |
13F
|
Company |
0.02%
|
21,591
|
$9,548 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.02%
|
20,309
|
$8,981 | — | 31 Mar 2025 | |
| Corebridge Financial, Inc. |
13F
|
Company |
0.02%
|
19,804
|
$8,757 | — | 31 Mar 2025 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.02%
|
19,314
|
$8,541 | — | 31 Mar 2025 | |
| Creative Planning |
13F
|
Company |
0.02%
|
19,018
|
$8,410 | — | 31 Mar 2025 | |
| Capital Analysts, LLC |
13F
|
Company |
0.02%
|
16,300
|
$7,000 | — | 31 Mar 2025 | |
| INTECH INVESTMENT MANAGEMENT LLC |
13F
|
Company |
0.02%
|
15,620
|
$6,907 | — | 31 Mar 2025 | |
| FMR LLC |
13F
|
Company |
0.02%
|
15,605
|
$6,901 | — | 31 Mar 2025 |
Institutional Holders of Verrica Pharmaceuticals Inc. - Common Stock, $0.0001 par value (VRCA) as of Q2 2025
As of 30 Jun 2025,
Verrica Pharmaceuticals Inc. - Common Stock, $0.0001 par value (VRCA) was held by
4 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
194,004 shares.
The largest 4 holders included
MARSHALL WACE, LLP, BECK MACK & OLIVER LLC, EverSource Wealth Advisors, LLC, and SBI Securities Co., Ltd..
This page lists
4
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q4 2025 Across Filers
Q4 2025 holders
49
Q2 2025 holders
4
Holder diff
-45
| Investor | Q4 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.